The activation of the PI3K/AKT signaling pathway is associated with nearly 70% of CRC cases, while at the same time, inhibition of the signaling pathway is considered a target for CRC therapy (Malinowsky et al., 2014). This evidence concerns the gene AKT1 and colorectal carcinoma.